• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
  LongeCity
              Advocacy & Research for Unlimited Lifespans

Photo
- - - - -

Resveratrol Comments And Questions


  • Please log in to reply
56 replies to this topic

#31 macanizer

  • Guest
  • 53 posts
  • 0

Posted 16 September 2007 - 03:29 PM

The results, thus, indicate that at low dose [25 mg/ kg], resveratrol exerts survival signal by upregulating anti-apoptotic and redox protein PARP-1, Bcl-2 and Ref-1 and down regulating proapoptotic p53 and p-Bad proteins.


Those of us taking 500mg a day are only getting about a ¼ of the low dose then? At 25mg/kg I should be taking 1.8g a day! I'll start taking 1g for now, after I run out of the 50% t-res I'll switch to the high purity stuff to get closer to this 2g "low dose"

inawe, thanks for posting that study

#32 inawe

  • Guest
  • 653 posts
  • 3

Posted 16 September 2007 - 04:37 PM

Thanks for the data inawe. This type of data is extremely valuable for relatively new supps such as t-res. Especially when the safe upper limit is not yet known.

You're welcome.
Haven't found the complete paper yet or more information about that subject. Besides worrying me, because I'm dosing above what they say is the safe zone, it reminded me that resveratrol is not a magic potion but just a supplement. As for any other supplement, benefits as a function of dose must follow an inverted U-shape curve.
I think that it was Guarente who said you cannot kill a mouse giving it too much resveratrol. Based on that Sirtris has announced trials with up to 5 gr/day. And as well as others, I have been increasing my daily dose.
But we are somewhat different from mice (although I like cheese as much as they do). Mice don't usually get heart attacks. They are killed by cancer, mousetraps or researchers.
To mimic heart attack, ischemia is induced in mice. In PMID: 17225566 [PubMed - indexed for MEDLINE] and other papers, Das et al., report that resveratrol attenuates the injury due to ischemia (nice boy resveratrol). But then they increased the dosage and in Dudley and Das, it is reported that a high resveratrol dose can be damaging.
Seems that in high numbers, resveratrol molecules gang up and go out to kill damaged cells. They kill cancer cells which is very good. But the also kill heart cells damaged by infarction, which is terrible.
I think this research is so important that it should either be reproduced or shown to be mistaken. If it's correct many people including me, will have to adjust resveratrol dose. And it will deal a very hard blow to Sirtris.

sponsored ad

  • Advert
Click HERE to rent this advertising spot for SUPPLEMENTS (in thread) to support LongeCity (this will replace the google ad above).

#33 tintinet

  • Guest
  • 1,972 posts
  • 503
  • Location:ME

Posted 16 September 2007 - 04:58 PM

And yet mice are not men (well, not all, at least! :) ). As noted above, more studies are required to make firm conclusions regarding human dosing. Still, all of who supplement t-resv. are treading uncertain ground.

#34 VP.

  • Guest
  • 498 posts
  • 200

Posted 17 September 2007 - 02:11 AM

An interesting but not peer reviewed study showing a host of genes changed by taking resveratrol. The study done in mice is being used to file a patent application. Some excerpts:

Animals and dietary manipulations

Male -3603F1 mice (6-7 weeks of age) were purchased from Harlan Sprague Dawley. Mice were housed singly and provided water ad libitum. The control group (OC, N=5) was fed 98 kcal/week of modified AIN-93M semi-purified diet (Bio-serv, Frenchtown, NJ), which provides approximately 15% fewer calories than the average ad libitum dietary intake. The treatment group (RES, N=5) was fed the same caloric intake as controls, but were supplemented with resveratrol 50mg/kg diet (w/w) (3,4',5-Trihydroxy-trans-stilbene; Sigma) from 14 months of age. Animals (OC and RES) were sacrificed at 30 months of age. Young animals were sacrificed at 5 months of age (YC, N=5). Hearts from all abovementioned groups were collected, immediately frozen in liquid nitrogen and stored at -80 0C until analysis.
Gene expression data were obtained using the Affymetrix Mouse Genome 430 2.0 array containing 45,101 probe sets. All steps, as detailed below, were performed using the most recent version of probe set (Mouse Genome 430. 2.0 array probe set annotations available from Affymetrix at 23 August 2005). Signal intensity was determined using Affymetrix's GeneChip Operating Software version 1.3. Data analysis was performed using Genedata Expressionist® Pro, version 2.0.

1) genes changed with age Genes which changed with age (ageing markers) were selected by comparing YC and OC groups. To determine if there was a change in the expression of a gene with resveratrol, comparisons were made between OC and RES mice, respectively. Significantly changed genes were selected using the n-fold test, with change > 1.25-fold or consistently present in one group but absent in other groups, in combination with the two-sample test, where significance was tested at P<0.01 (both the t-test and Welch test were used to calculate the statistical significance).

2) genes unchanged with age

The genes which were unchanged with age (non-ageing markers) were selected by comparing YC and OC groups, first filtered with a variance <0.05, then further selected with fold of change <1.25-fold, plus 2-group test, where significance was tested at p>0.01 (i.e. significantly unchanged between YC and OC groups). Similarly, significantly-changed genes were determined using either fold of change (>1.25-fold) or consistently present in one group but absent in other groups. Two-tailed t-test and Welch test were both used to calculate the statistical significance, where P<0.01 was considered as a significant change.
The genome-wide gene expression in heart tissue in groups of young, old and resveratrol- fed mice was monitored using the mouse Affymetrix gene array. Among the 26,000 probe sets available on the chip, 1285 genes were significantly changed between the groups of young mice and old mice (at least 1.25-fold, where p<0.01 ). Among them, 501 genes were up- and 724 were down-regulated in the group of old mice. Within the 1285 genes, the expression of 585 genes in the resveratrol treated group were changed in the direction of the group of younger adult mice (45.5%, see table II), indicating a significant effect of resveratrol in maintaining the heart in a healthy and young state To summarize the scope of the resveratrol effect, in the 1023 above mentioned genes changed by resveratrol treatment, 342 resembled or exceeded the expression level of the young group (58.1 %); 62 genes were at a level of 80- 90% compared to the young group and 53 genes reached a level of 70- 80%. [B]Therefore, in spite of being of the same biological age as the mice in the group of old animals, old animals fed a resveratrol-supplemented diet showed a gene profile surprisingly close to that of the young animals.
For the purposes of the invention, the dosage requirements for resveratrol, a derivative, metabolite or analogue are not narrowly critical Amounts of up to about 30 mg/kg body weight per day or even higher, depending of the nature of the mammal concerned and its condition and requirements may be administered Thus, for a human adult (weighing about 70 kg) the dosage may be up to about 2000 mg/day In a particular embodiment of the invention, the dosage for a human adult (weighing about 70 kg) is up to about 500 mg/day, especially up to about 500 mg/day Suitably, the dosage is no less than 0 5 mg In a particular embodiment of the invention, the dosage for a human adult (weighing about 70 kg) is no less than 2 mg , especially is no less than 5 mg If administered in a food or beverage the amount of resveratrol, a derivative, metabolite or analogue thereof contained therein is suitably no less than about 0 2 mg per serving In another embodiment of the invention such amount is no less than 2 mg per serving On the other side, resveratrol, a derivative, metabolite or analogue thereof may be administered in a food or beverage in an amount of up to 100, 200 or 500 mg per serving If resveratrol, a derivative, metabolite or analogue thereof is adminstered as a pharmaceutical formulation such formulation may contain up to about 100, 200 or 500 mg per solid dosage unit, e g ,
In conclusion, the present study showed that the gene expression profile of an adult mammal treated orally with resveratrol is closer to a healthy younger adult mammal than to a mammal having the same chronological age This younger gene expression profile in resveratrol treated animals promotes the state of wellness in the animalsand rejuvenates the animals

I'm not sure what it all means but I hope it's a good thing to have all these genes expressed.




http://www.wipo.int/...71&DISPLAY=DESC

#35 luv2increase

  • Guest
  • 2,529 posts
  • 37
  • Location:Ohio

Posted 17 September 2007 - 02:37 AM

I can't wait until the future when there will be computer programs where a molecular structure can be added into a virtual human DNA model and all outcomes are exactly the same as in real life. There would be no more need of damn mice and monkeys anymore! Oh if only that time were now, there would be wayyy fewer questions and problems.

#36 wydell

  • Topic Starter
  • Guest
  • 503 posts
  • -1

Posted 17 September 2007 - 03:37 AM

If I could change the Topic name, I would. I don't think I really should have used the word "skepticism" as that has a pejorative meaning.

My view is more agnostic. In other words, I believe it is too early to tell whether there is a benefit or not in humans through oral consumption of plain old trans-res.

And while my gut tells me there is low risk of potential harm, there is no definitive data in humans on that as well.


If I could, I would rename the Topic -Res Studies. Though I am sure just about every res study is posted in the 500MG thread in any event.

#37 niner

  • Guest
  • 16,276 posts
  • 2,000
  • Location:Philadelphia

Posted 17 September 2007 - 04:01 AM

Velopismo, those genechip results are pretty impressive. While their patent is a bit comical (kinda late to the party, aren't they?), they have discovered a number of ageing markers. They aren't the first people to do that either, but I guess my point is that the methodology is really powerful. I hope we see a lot more of it, particularly in application to humans.

#38 Brainbox

  • Member
  • 2,860 posts
  • 743
  • Location:Netherlands
  • NO

Posted 17 September 2007 - 10:59 AM

If I could change the Topic name, I would. I don't think I really should have used the word "skepticism" as that has a pejorative meaning. My view is more agnostic.

There you are. :))

I think it is not in Sirtris' interest to publish the study, only studies on their SRT501 formulation and resveratrol analogues. Anyone can market an herbal extract, after all, so why validate it? Or am I too paranoid? They wouldn't withhold a scientific study, would they?

It was my impression that the healthy mice study was ongoing and therefore inevitably would produce publishable results. Anyway, the reason that this preliminary study that originated before Sirtris was even grounded would not benefit the new SRT501 product didn't come to my mind. That could very well be the reason for not publishing, which would make my approach look to be on the paranoid side indeed.
On the other hand, despite a lot of promising studies that are available, no doubt about that, where's the indication or even proof that T-Res mimics Sir2 / SIRT1 / sirtuin 1 activation and / or AAK-2 / AMPK activation and consequently causes practical, actual and proven increase of lifespan, like calorie restriction does in healthy individuals?

Thanks for the data inawe. This type of data is extremely valuable for relatively new supps such as t-res. Especially when the safe upper limit is not yet known.

Agreed!

Rephrased my question so that it reflects my concerns more accurately

Edited by brainbox, 17 September 2007 - 12:11 PM.


#39 maxwatt

  • Guest, Moderator LeadNavigator
  • 4,949 posts
  • 1,625
  • Location:New York

Posted 17 September 2007 - 01:53 PM

It was my impression that the healthy mice study was ongoing and therefore inevitably would produce publishable results. Anyway, the reason that this preliminary study that originated before Sirtris was even grounded would not benefit the new SRT501 product didn't come to my mind. That could very well be the reason for not publishing, which would make my approach look to be on the paranoid side indeed.
On the other hand, despite a lot of promising studies that are available, no doubt about that, where's the indication or even proof that T-Res mimics Sir2 / SIRT1 / sirtuin 1 activation and / or AAK-2 / AMPK activation and consequently causes practical, actual and proven increase of lifespan, like calorie restriction does in healthy individuals?


There is convincing evidence resveratrol induces AMPK activation:

1: 
Park CE, Kim MJ, Lee JH, Min BI, Bae H, Choe W, Kim SS, Ha J.
Resveratrol stimulates glucose transport in C2C12 myotubes by activating AMP-activated protein kinase.
Exp Mol Med. 2007 Apr 30;39(2):222-9.
PMID: 17464184 [PubMed - indexed for MEDLINE]
2: 
Dasgupta B, Milbrandt J.
Resveratrol stimulates AMP kinase activity in neurons.
Proc Natl Acad Sci U S A. 2007 Apr 24;104(17):7217-22. Epub 2007 Apr 16.
PMID: 17438283 [PubMed - indexed for MEDLINE]
3: 
Hwang JT, Kwak DW, Lin SK, Kim HM, Kim YM, Park OJ.
Resveratrol induces apoptosis in chemoresistant cancer cells via modulation of AMPK signaling pathway.
Ann N Y Acad Sci. 2007 Jan;1095:441-8.
PMID: 17404056 [PubMed - indexed for MEDLINE]
4: 
Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA.
Resveratrol improves health and survival of mice on a high-calorie diet.
Nature. 2006 Nov 16;444(7117):337-42. Epub 2006 Nov 1.
PMID: 17086191 [PubMed - indexed for MEDLINE]
5: 
Zang M, Xu S, Maitland-Toolan KA, Zuccollo A, Hou X, Jiang B, Wierzbicki M, Verbeuren TJ, Cohen RA.
Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice.
Diabetes. 2006 Aug;55(8):2180-91.
PMID: 16873680 [PubMed - indexed for MEDLINE] 


I believe Sirtris (and others) have determined the structure of Sirt1 and perhaps other human Sirtuin genes (there at least seven) and are synthesizing substances with no relationship to resveratrol, that fit in the appropriate receptors to activate these genes.

#40 platypus

  • Guest
  • 2,386 posts
  • 240
  • Location:Italy

Posted 17 September 2007 - 03:09 PM

Does anyone know if there are any human studies that demonstrate benefits from crack cocaine?  I have already started  adding coffee and alcohol in moderation :)

Medicinal crack?? [lol]

#41 dannov

  • Guest
  • 317 posts
  • -1

Posted 17 September 2007 - 03:35 PM

luv2increase, you're very opinionated and come off as ignorant to me, waving your finger in our faces about "overdosing" on Res and even misreading a fellow's post and then accusing him of being an addict. Just...stop.

Those of us who dose Resveratrol high do it to ensure that we get some through our system due to its poor oral bioavailability. The generally accepted upper limit is 7g when compared to mice, though there are no human studies to substantiate this. All that we know for sure is that Res has low bioavailability, so it would be in our best interest to not waste our money taking small amounts of it when it could very well have little to no effect in such small quantities due to glucorinidation and sulfation in the liver.

For those wondering, I use the same Res powder as Max (98.2-7%), dissolve 4g of it in 2g of Miralax (produces a nice, fine milky solution), and wash down 2 Bioperine pills (20mgs of Piperine) with it to help inhibit sulfation for better bioavailability. Today will be day 3 of supplementation. ^_^

#42 Anthony_Loera

  • Life Member
  • 3,168 posts
  • 745
  • Location:Miami Florida

Posted 17 September 2007 - 04:40 PM

luv2increase,

please check the Nature publication dated Jun 2006 called "Therapeutic potential of resveratrol: the in vivo evidence" by Joseph A. Baur and David A. Sinclair.

In his conclusions, David Sinclair talks about the high cost of resveratrol when calculating and administering 100mg per kg on a typical human. He states it would take about 2.7kg a year of resveratrol, which comes out to about 7.39 grams a day.

What I find funny about this conversation, is the fact that the wine folks constantly blog about how wine is incredibly healthy because of resveratrol that has been shown in studies to have x number of benefits, but never say anything about the amount of resveratrol studied... and how much wine is needed to be consumed to equal the dosage in the studies.

Marketing at it's finest.

#43 luv2increase

  • Guest
  • 2,529 posts
  • 37
  • Location:Ohio

Posted 18 September 2007 - 12:30 AM

luv2increase, you're very opinionated and come off as ignorant to me, waving your finger in our faces about "overdosing" on Res and even misreading a fellow's post and then accusing him of being an addict.  Just...stop.



I said it sounded like addicting behavior.

Ignorant? No, I'm not ignorant. I am just realistic. I will tell you this. We all want one thing and strive for the same goals. They are health and immortality. Anything that could possibly stand in the way of these two things, I will question and be concerned about.

I will also tell you this. The grand majority of information on resveratrol currently is VERY good! The 'one' negative study that inawe posted was done in animals. Hey, guess what... I don't think that all animal studies correlate 100% for humans. Also, there was 'one' negative study about NAC which I'm sure you know just came out recently. Hey guess what... I'm still taking NAC and at 600mg in the morning. Why? Because the grand majority on NAC has also been positive.

I guess I am a hypocrite in a way. Sorry for that and sorry if I came out that way (being an ass). That is something that I am trying to work on. It is one of my character flaws (being an ass) that I am not proud of.


The part of the computer program and entering DNA and chemical molecule into it blah blah blah was in no way sarcastic or anything negative whatsoever. It was a sincere thought.

#44 Brainbox

  • Member
  • 2,860 posts
  • 743
  • Location:Netherlands
  • NO

Posted 18 September 2007 - 04:03 AM

It was my impression that the healthy mice study was ongoing and therefore inevitably would produce publishable results. Anyway, the reason that this preliminary study that originated before Sirtris was even grounded would not benefit the new SRT501 product didn't come to my mind. That could very well be the reason for not publishing, which would make my approach look to be on the paranoid side indeed.
On the other hand, despite a lot of promising studies that are available, no doubt about that, where's the indication or even proof that T-Res mimics Sir2 / SIRT1 / sirtuin 1 activation and / or AAK-2 / AMPK activation and consequently causes practical, actual and proven increase of lifespan, like calorie restriction does in healthy individuals?


There is convincing evidence resveratrol induces AMPK activation:

1: 
Park CE, Kim MJ, Lee JH, Min BI, Bae H, Choe W, Kim SS, Ha J.
Resveratrol stimulates glucose transport in C2C12 myotubes by activating AMP-activated protein kinase.
Exp Mol Med. 2007 Apr 30;39(2):222-9.
PMID: 17464184 [PubMed - indexed for MEDLINE]
2: 
Dasgupta B, Milbrandt J.
Resveratrol stimulates AMP kinase activity in neurons.
Proc Natl Acad Sci U S A. 2007 Apr 24;104(17):7217-22. Epub 2007 Apr 16.
PMID: 17438283 [PubMed - indexed for MEDLINE]
3: 
Hwang JT, Kwak DW, Lin SK, Kim HM, Kim YM, Park OJ.
Resveratrol induces apoptosis in chemoresistant cancer cells via modulation of AMPK signaling pathway.
Ann N Y Acad Sci. 2007 Jan;1095:441-8.
PMID: 17404056 [PubMed - indexed for MEDLINE]
4: 
Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA.
Resveratrol improves health and survival of mice on a high-calorie diet.
Nature. 2006 Nov 16;444(7117):337-42. Epub 2006 Nov 1.
PMID: 17086191 [PubMed - indexed for MEDLINE]
5: 
Zang M, Xu S, Maitland-Toolan KA, Zuccollo A, Hou X, Jiang B, Wierzbicki M, Verbeuren TJ, Cohen RA.
Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice.
Diabetes. 2006 Aug;55(8):2180-91.
PMID: 16873680 [PubMed - indexed for MEDLINE] 

Ok, but a point is that the healthy mice study, that was ongoing (according to what I did understand) could have provided us with data on actual lifespan benefits under healthy condition, putting the jig-saw puzzle together. Not publishing them is a missed opportunity!

#45 dannov

  • Guest
  • 317 posts
  • -1

Posted 18 September 2007 - 01:47 PM

It's OK luv, I understand. :)

#46 tintinet

  • Guest
  • 1,972 posts
  • 503
  • Location:ME

Posted 18 September 2007 - 03:09 PM

BTW, I have spoken to one individual who had experience with ADHD meds who claimed high dose trans-resv. was a better high than Adderall....

#47 dannov

  • Guest
  • 317 posts
  • -1

Posted 18 September 2007 - 08:31 PM

I've seen someone snort Adderall crushed in front of my face (moron), but I've never heard of it giving a high from oral ingestion. However, everyone that I know that has used it (a good deal) report that it greatly increases the ability to hone in/focus on something. That's about it. Could be just my lack of knowledge, but never heard of oral ingestion giving a high.

#48 jonn

  • Guest
  • 1 posts
  • 0

Posted 24 September 2007 - 06:41 AM

Members of this forum have been speculating about the makeup of SRT501. There's no need to speculate. Read the patent. SRT501 is resveratrol mixed with Captisol, a special formulation of beta cyclodextrin. (Also the secret ingredient in Febreeze, made from corn starch.) The SRT501 patent spells out the amounts of each substance used to make the formula, the equipment and processes used to mix it and the sources for the raw materials. Sinclair said the formula now being used in Type 2 diabetes human trials is a thousand times more powerful than resveratrol by itself.

#49 maxwatt

  • Guest, Moderator LeadNavigator
  • 4,949 posts
  • 1,625
  • Location:New York

Posted 24 September 2007 - 10:41 AM

Members of this forum have been speculating about the makeup of SRT501. There's no need to speculate. Read the patent. SRT501 is resveratrol mixed with Captisol, a special formulation of beta cyclodextrin. (Also the secret ingredient in Febreeze, made from corn starch.) The SRT501 patent spells out the amounts of each substance used to make the formula, the equipment and processes used to mix it and the sources for the raw materials. Sinclair said the formula now being used in Type 2 diabetes human trials is a thousand times more powerful than resveratrol by itself.


Do you have the patent number handy?

#50 adamb

  • Guest
  • 10 posts
  • 0

Posted 24 September 2007 - 01:06 PM

Since I did not want to open another Resveratrol thread, I pose my question in this one:
I wonder whether you have got any experiences or informations about interactions between Resveratrol and a Protone Pump Inhibitor (PPI) like Omeprazole or taking Resveratrol as GERD/LPR patient in general?

#51 tintinet

  • Guest
  • 1,972 posts
  • 503
  • Location:ME

Posted 24 September 2007 - 01:54 PM

Experience with GERD: don't notice any difference pre- and post high dose trans-resveratrol.

I go off and on PPIs. Recently I had a bout of generalized malaise with arthralgia, Raynaud's syndrome, etc. I included PPIs among etiologic suspects and stopped usin' 'em at that time (few months ago.)

#52 Anthony_Loera

  • Life Member
  • 3,168 posts
  • 745
  • Location:Miami Florida

Posted 24 September 2007 - 02:21 PM

Members of this forum have been speculating about the makeup of SRT501. There's no need to speculate. Read the patent. SRT501 is resveratrol mixed with Captisol, a special formulation of beta cyclodextrin. (Also the secret ingredient in Febreeze, made from corn starch.) The SRT501 patent spells out the amounts of each substance used to make the formula, the equipment and processes used to mix it and the sources for the raw materials. Sinclair said the formula now being used in Type 2 diabetes human trials is a thousand times more powerful than resveratrol by itself.



SRT501 is a thousand times more powerful? From the chart (see slide 17) here:

it is about 202% from regular rsv:
http://www.revgenetics.com/sirtris.htm

Are you sure you aren't talking about the NCE's?

A

#53 hormesis

  • Guest
  • 38 posts
  • 0

Posted 27 September 2007 - 09:04 PM

Here's the patent (Doesn't read quite as clear as a cookbook recipe though):

http://appft1.uspto....RT501&RS=SRT501

[1171] Typically, micronized drug dispersions contain a discrete phase of a drug substance as described above having a surface modifier adsorbed on the surface thereof. Useful surface modifiers are believed to include those which physically adhere to the surface of the drug substance but do not chemically bond to the drug. Suitable surface modifiers can preferably be selected from known organic and inorganic pharmaceutical excipients. Such excipients include various polymers, low molecular weight oligomers, natural products and surfactants, such as nonionic and anionic surfactants. Representative examples of excipients include gelatin, casein, lecithin (phosphatides), gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glyceryl monostearate, cetostearl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, e.g., macrogol ethers such as cetomacrogol 1000, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, e.g., the commercially available Tweens (Tween 80), polyethylene glycols, polyoxyethylene stearates, colloidol silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethylcellulose calcium, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethycellulose phthalate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol, and polyvinylpyrrolidone (PVP). Most of these excipients are described in detail in the Handbook of Pharmaceutical Excipients, published jointly by the American Pharmaceutical Association and The Pharmaceutical Society of Great Britain, the Pharmaceutical Press, 1986, the disclosure of which is hereby incorporated by reference in its entirety. The surface modifiers are commercially available and/or can be prepared by techniques known in the art.

[0012] Another aspect of the present invention provides a composition that includes nanoparticles comprising a sirtuin modulator, or a pharmaceutically acceptable salt, prodrug or metabolic derivative thereof. Such particles typically have a mean diameter of 50 nm to 500 nm, such as 100 nm to 200 nm.

[0013] A further aspect of the present invention provides a composition that includes a cyclodextrin and a sirtuin modulator, or a pharmaceutically acceptable salt, prodrug or metabolic derivative thereof. Such compositions are advantageously liquids or lyophilized powders (e.g., water-soluble powders).

#54 hormesis

  • Guest
  • 38 posts
  • 0

Posted 27 September 2007 - 09:19 PM

(I wonder if we can avoid the excessive stirring and get smaller particles by dissolving the resveratrol in everclear before adding to a standard lecithin/water emulsion)
Here's the section of interest:

Example 9

Preparation of Resveratrol Cyclodextran Solutions and Lyophilized Powders

[1344] Two resveratrol formulations were chosen for evaluation as prototype drug products, resveratrol solutions in either 40% Captisol or 10% Captisol. Specifically, a low concentration resveratrol solution (20 mM or 4.57 mg/mL) in 10% Captisol (w/v) was produced on a 20 mL scale and lyophilized vials produced (1 mL per vial). Lyophilized vials containing 10% Captisol control vehicle were also manufactured. A high concentration resveratrol solution (150 mM) in 40% Captisol (w/v) was produced on a 500 mL scale, and supplied as a lyophilized product (5 mL per vial). Lyophilized vials containing 40% Captisol control vehicle were also manufactured.

[1345] The low concentration resveratrol solution was prepared by adding 136.99 mg resveratrol to 30 mL 10% Captisol (CyDex, Lot # CY-04A-05006), and mixed for 1 hour at ambient temperature. The initial solution had a pH of 5.02 and with a concentration of 15.4 mM in resveratrol. The solution was filtered through a 0.20 .mu.m nylon syringe filter (Fisher #09-719C), resulting in a solution at 14.9 mM in resveratrol with a pH of 4.83. The 10% Captisol control vehicle solution had a pH of 4.78 before filtration and a pH of 4.76 after filtration. The filtered solutions were dispensed into vials (1.0 mL solution into 3 mL vial, Wheaton #223684), and lyophilized. At the end of the lyophilization cycle, the vials were sealed under vacuum and a cap crimped over the septa.

[1346] The lyophilized resveratrol product was an off-white cake. The material reconstituted in .about.20 seconds after the addition of 1.0 mL water. The reconstituted resveratrol solution was clear, with no visible particulates, having a pH of 5.91, and a measured concentration of 14.4 mM resveratrol. The lyophilized control vehicle product was a white cake. The material reconstituted in .about.20 seconds after the addition of 1.0 mL water. The reconstituted control vehicle was clear, with no visible particulates, and having a pH of 5.82.

[1347] The high concentration resveratrol formulation (150 mM SRT501 in 40% Captisol (w/v) on a 500 mL scale) was prepared as follows. A 40% Captisol (w/v) was prepared by placing 560 g of Captisol (CyDex, Lot # CY-04A-05006) into a 4 L beaker. A large stir bar was added to the beaker that was then placed on a large stir plate. In-house Milli-Q water was added to bring the volume in the beaker to .about.1.3 L. The solution was mixed vigorously for 1 hour until clear. At times, a spatula was used to free the stir bar and dislodge undissolved material from the sides of the vessel. The solution was transferred to a 2 L graduated cylinder. Approximately 100 mL of water was used to rinse the beaker and was added to the graduated cylinder, bringing the final volume to 1.4 L. The solution was mixed thoroughly until clear.

[1348] The high concentration resveratrol solution was prepared by mixing 600 mL of 40% Captisol in a 1 L beaker with 24.0 g resveratrol and stirring vigorously (the target concentration would be 175 mM resveratrol in 40% Captisol (w/v) if all the material dissolved). The solution was stirred for 35 minutes, followed by sonication for 1 hour. The solution was stirred for an additional 50 minutes, followed by sonication for an additional hour. At this point, solid material was still present in the sample. An aliquot was removed for analysis. The pH was measured at 4.76 and the concentration was measured by HPLC to be 55 mM resveratrol. Because the solution appeared cloudy at this time, three portions were separated to try alternate mixing methods. Approximately 200 mL was transferred to a 500 mL volumetric flask and was sonicated for 45 min, approximately 300 mL was vigorously mixed with an overhead mixer for 90 minutes, and approximately 100 mL was homogenized for 25 minutes. None of the three portions appeared clear. A sample of the homogenized solution was removed for concentration analysis and had a concentration of 74 mM resveratrol. The portions were combined and were stirred at ambient temperature overnight protected from light. The following morning, using an aseptic technique in the laminar flow hood, the solution was sterile filtered via a Nalgene 90 mm filter unit (Cat# 167-0020; 0.02 PES membrane). The concentration was again measured and determined to be 168 mM resveratrol in 40% Captisol.

[1349] The control vehicle (40% Captisol (w/v)) was also prepared as follows. 700 mL of 40% Captisol was transferred into a 1 L beaker. The solution was sonicated for a total of 2 hours. The solution was then stored at ambient temperature overnight. Using an aseptic technique in the laminar flow hood, the solution was sterile filtered via a Nalgene 90 mm filter unit (Cat# 167-0020; 0.02 PES membrane).

[1350] In the laminar flow hood, 30 mL molded glass vials, which had been sterilized by an autoclave, were filled with 5 mL of control vehicle or resveratrol solution. The vials were lyophilized in three batches according to the previously developed lyophilization cycle. The vials were stoppered under vacuum, sealed, and labeled. The resveratrol/Captisol vials contained a cake with an off-white appearance. The sample quickly reconstituted to a slightly yellow clear solution with the addition of water. 3.7 mL of water should be added to a vial to produce the original concentration of 40% Captisol.

http://www.cydexinc.com/captisol.asp

#55 malbecman

  • Guest
  • 733 posts
  • 156
  • Location:Sunny CA

Posted 27 September 2007 - 09:21 PM

Sigh, sometimes I think the purpose the whole patent is to just bury the true facts in a whole lot of verbage. I guess thats why IP lawyers get their $$$$.

Here is a section from the patent on the formulation:

[1136] Exemplary formuations of the invention include nicotinamide riboside dissolved in phosphate-buffered saline (PBS), reservatrol together with beta-cyclodextrin (e.g., 10-20 mM or 14-16 mM resveratrol in 5-15% (about 10%) beta-cyclodextrin), and resveratrol nanoparticles together with a cellulose derivative (e.g., hydroxypropylmethylcellulose (HPMC)) and dioctyl sodium sulfosuccinate (DOSS) (e.g., 15-25% resveratrol nanoparticles, 1-1.5% HPMC, 0.01-0.10% DOSS). Each of these formulations can optionally include additional active agents, buffers (e.g., PBS), preservatives and the like. Preferably, such formulations are isotonic.


Here is another "nice" section. Rectal administration anyone??? [lol]

1143] These compounds may be administered to humans and other animals for therapy by any suitable route of administration, including orally, nasally, as by, for example, a spray, rectally, intravaginally, parenterally, intracistemally and topically, as by powders, ointments or drops, including ophthalmically, buccally and sublingually.



Here's the patent (Doesn't read quite as clear as a cookbook recipe though):

http://appft1.uspto....RT501&RS=SRT501

[1171] Typically, micronized drug dispersions contain a discrete phase of a drug substance as described above having a surface modifier adsorbed on the surface thereof. Useful surface modifiers are believed to include those which physically adhere to the surface of the drug substance but do not chemically bond to the drug. Suitable surface modifiers can preferably be selected from known organic and inorganic pharmaceutical excipients. Such excipients include various polymers, low molecular weight oligomers, natural products and surfactants, such as nonionic and anionic surfactants. Representative examples of excipients include gelatin, casein, lecithin (phosphatides), gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glyceryl monostearate, cetostearl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, e.g., macrogol ethers such as cetomacrogol 1000, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, e.g., the commercially available Tweens (Tween 80), polyethylene glycols, polyoxyethylene stearates, colloidol silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethylcellulose calcium, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethycellulose phthalate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol, and polyvinylpyrrolidone (PVP). Most of these excipients are described in detail in the Handbook of Pharmaceutical Excipients, published jointly by the American Pharmaceutical Association and The Pharmaceutical Society of Great Britain, the Pharmaceutical Press, 1986, the disclosure of which is hereby incorporated by reference in its entirety. The surface modifiers are commercially available and/or can be prepared by techniques known in the art.

[0012] Another aspect of the present invention provides a composition that includes nanoparticles comprising a sirtuin modulator, or a pharmaceutically acceptable salt, prodrug or metabolic derivative thereof. Such particles typically have a mean diameter of 50 nm to 500 nm, such as 100 nm to 200 nm.

[0013] A further aspect of the present invention provides a composition that includes a cyclodextrin and a sirtuin modulator, or a pharmaceutically acceptable salt, prodrug or metabolic derivative thereof. Such compositions are advantageously liquids or lyophilized powders (e.g., water-soluble powders).



#56 stephen_b

  • Guest
  • 1,735 posts
  • 231

Posted 27 September 2007 - 10:09 PM

Here is another "nice" section.  Rectal administration anyone???  [lol]

Maybe they are trying to cover their asses? [lol]

Stephen

sponsored ad

  • Advert
Click HERE to rent this advertising spot for SUPPLEMENTS (in thread) to support LongeCity (this will replace the google ad above).

#57 Anthony_Loera

  • Life Member
  • 3,168 posts
  • 745
  • Location:Miami Florida

Posted 28 September 2007 - 04:26 AM

It appears the patent hasn't been awarded, and its been over a year.

I am not entirely sure it will be able to be patented as some rsv studies may serve as "prior art" for some parts of the patent, and it may be difficult to award. Then again, I may be wrong on it.
I think someone already has a patent on micronizing rsv with lecithin If I remember right, as part of the micronizing method... (cough..)Pfizer(cough)

I got to go look for it again... its late, and I could be wrong about that...
A




2 user(s) are reading this topic

0 members, 2 guests, 0 anonymous users